EX-FILING FEES 2 exhibit107-resalesx3.htm EX-FILING FEES Document
Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Spyre Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type
Security Class Title
Fee Calculation or Carry Forward Rule
Amount Registered
Proposed Maximum Offering Price Per Unit
Maximum Aggregate Offering Price
Fee Rate
Amount of Registration Fee
Carry Forward Form Type
Carry Forward File Number
Carry Forward Initial effective date
Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to Be Paid
Equity
Common stock, $0.0001 par value per share(1)
Rule 457(c)
46,330,799(2)
$28.40(3)
 $1,315,794,691.60(3)
0.00014760
$194,211.30
Carry Forward Securities
Carry Forward Securities
N/AN/AN/AN/AN/AN/A
N/A
N/A
N/A
Total Offering Amounts
$1,315,794,691.60
$194,211.30
Total Fees Previously Paid
N/A
Total Fee Offsets
N/A
Net Fee Due
$194,211.30
__________________
(1)Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers such an indeterminate amount of shares of common stock as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.
(2)The amount registered consists of up to (i) 31,137,912 shares of Common Stock, (ii) 13,841,800 shares of Common Stock issuable upon the conversion of 346,045 shares of Series A Preferred Stock, (iii) 666,680 shares of Common Stock issuable upon the conversion of 16,667 shares of Series B Preferred Stock, and (iv) 684,407 shares of Common Stock issuable upon exercise of warrants to purchase Common Stock.
(3)Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the shares of Common Stock on The Nasdaq Global Select Market on September 16, 2024 (such date being within five business days of the date that this registration statement was first filed with the Securities and Exchange Commission, in accordance with Rule 457(c) under the Securities Act).